Dimebon IR ( DrugBank: Dimebon )

---

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
8	ハンチントン病	2

8. ハンチントン病

---

臨床試験数 : 242 /  薬物数 : 205 - (DrugBank : 62) / 標的遺伝子数 : 85 - 標的パスウェイ数 : 159

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00990613 (ClinicalTrials.gov)	October 2009	6/10/2009	A Study Evaluating The Absorption Of Dimebon Into The Body From A Dimebon Solution Applied To The Skin	A Phase 1, Fixed Sequence, Cross-Over Study To Investigate The Single Dose Pharmacokinetics Of A Dimebon (Latrepirdine) Transdermal Solution Relative To The Immediate Release Formulation In Older Adults	Alzheimer's Disease;Huntington's Disease	Drug: Dimebon IR;Drug: Dimebon Transdermal	Pfizer	Medivation, Inc.	Completed	50 Years	85 Years	Both	19	Phase 1	United States
2	NCT00988624 (ClinicalTrials.gov)	October 2009	1/10/2009	A Study In Healthy Volunteers To Estimate The Pharmacokinetics Of Four Modified-Release Formulations Of Dimebon (Latrepirdine)	A Phase 1, Randomized, Open-Label, Single Dose Cross-Over Study In Healthy Volunteers To Estimate The Pharmacokinetics Of Four Modified-Release Formulations Of Dimebon (Latrepirdine)	Alzheimer's Disease;Huntington Disease	Drug: Dimebon IR Tablet;Drug: Dimebon MR1;Drug: Dimebon MR2;Drug: Dimebon MR3;Drug: Dimebon MR4	Pfizer	Medivation, Inc.	Completed	18 Years	55 Years	Both	20	Phase 1	United States